相关实验视频
Updated: Mar 12, 2026

06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.6K
抑制胰岛素介导的β2上腺素受体激活 防止糖尿病相关的心脏功能障碍
Qingtong Wang1,2, Yongming Liu1,3, Qin Fu1,4
1Department of Pharmacology, University of California at Davis, CA 95616, USA.
Circulation
|November 6, 2016
概括
在2型糖尿病和肥胖症中,高胰岛素血症通过增加PDE4D表达增加心力衰竭的风险. 向β- 2上腺素受体或GRK2可以预防这种心脏功能障碍.
科学领域:
- 心脏病学
- 内分泌学
- 分子生物学
背景情况:
- 二型糖尿病 (DM) 和肥胖是心力衰竭的独立危险因素.
- 这些疾病与心力衰竭的关联机制尚未完全理解.
- 在2型糖尿病和肥胖中常见的高胰岛素血症被假定会导致心脏功能障碍.
研究的目的:
- 在2型糖尿病和肥胖症的背景下,研究高胰岛素血症对心脏功能障碍的作用.
- 阐明胰岛素引起的心脏不良影响的分子信号通路.
- 确定2型糖尿病和肥胖患者预防或治疗心力衰竭的潜在治疗点.
主要方法:
- 在野生型小鼠和缺乏β2上腺素受体 (β2AR) 或β-arrestin2的小鼠中使用高脂肪饮食诱导肥胖和DM.
- 小鼠接受了卡维迪醇 (β阻断剂) 或G蛋白结合受体激酶2 (GRK2) 抑制剂的治疗.
- 评估了心脏信号通路和收缩功能.
主要成果:
- 高脂肪饮食增加了小鼠心中的固酶4D (PDE4D) 表达,与缩和扩张功能受损相关.
- 在DM患者的心脏中,PDE4D的表达也升高.
- 胰岛素诱导的PDE4D上调取决于胰岛素受体,胰岛素受体基质,GRK2,β-arrestin2和β2AR细胞外调节的激酶信号级联.
- 抑制或遗传删除β2AR或GRK2减弱的胰岛素诱导信号和PDE4D诱导,防止DM相关的心脏功能障碍.
结论:
- 通过增加PDE4D表达,高胰岛素血症导致2型糖尿病心力衰竭和肥胖.
- 乙2上腺素受体 (β2AR) 和GRK2被确定为与2型糖尿病相关的心力衰竭的新疗法标.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
793
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
793
Hormones Regulating Blood Glucose
8.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.0K
Insulin: The Receptor and Signaling Pathways
5.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.5K
Carbohydrate Metabolism
14.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.8K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K

